Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

New drug regimen for Helicobacter pylori eradication, the investigators compare once daily dose dexlansoprazole levofloxacin based quadruple therapy and twice daily dose dexlansoprazole levofloxacin quadruple therapy for helicobacter pylori eradication.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ramathibodi Hospital
• Treatments: Dexlansoprazole; Lansoprazole; Levofloxacin; Ofloxacin

Criteria

Inclusion Criteria:

1. Age 18-75 year-patient

2. Diagnosed as positive Helicobacter Pylori testing by any of the following methods:

• Rapid urease test or Histology

3. Inform consent

Exclusion Criteria:

1. Previous history of Helicobacter pylori eradication

2. Contraindications or allergic reactions to the study drugs

3. Previous gastric surgery or advanced gastric cancer or other malignancy or other severe concurrent diseases

4. Decompensated Liver cirrhosis or chronic kidney disease (GFR< 30)

5. Mental disorders or alcohol or drug addiction

6. Pregnancy or lactation